ASH: Novartis Looks To Challenge Frontline DLBCL Standard Of Care With Next-Gen CAR-T

Although Novartis was the first company to win US Food and Drug Administration approval for a CAR-T cell therapy with Kymriah (tisagenlecleucel) back in 2017, the market has shifted in favor of competitors, particularly for diffuse large B-cell lymphoma (DLBCL). But the company is banking on data showing that its next-generation CAR-T agent rapcabtagene autoleucel can both improve response rates and offer greater convenience to patients thanks to its quick manufacturing time.

The Swiss drug maker presented data on 7 December at the American Society of Hematology annual meeting from its Phase II study of the CAR-T in patients with relapsed/refractory DLBCL....